Novavax Presents New Data From Non-Human Primate Ebola Challenge at the 7th International Symposium on Filoviruses
March 28 2015 - 9:00AM
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage
vaccine company focused on the discovery, development and
commercialization of recombinant nanoparticle vaccines and
adjuvants, today announced Gale Smith, Ph.D., Vice President,
Vaccine Development, will present, "Recombinant EBOV/Makona
Glycoprotein (GP) Nanoparticle Vaccine Produced in Sf9 Insect
Cells," at the 7th International Symposium on Filoviruses,
Saturday, March 28, 2015 at 10:15 a.m. at the Washington Marriott
Metro Center in Washington, D.C.
As part of his talk, Dr. Smith will present new data from a
second non-human primate (NHP) study which was conducted by the
National Institutes of Health, National Institute of Allergy and
Infectious Diseases, Division of Microbiology and Infectious
Diseases (NIH-NIAID-DMID). In that study, animals received two
injections of a 5µg dose of Novavax' Ebola GP Vaccine together with
its proprietary Matrix-M adjuvant and were then challenged with a
lethal dose of the Ebola virus. Similar to the previous NHP study,
the challenge was lethal for the control animals, whereas the
animals immunized with Novavax' EBOV GP Vaccine remain healthy 18
days post challenge.
"This data provides significant, independent confirmation that
our Ebola GP Vaccine is safe and effective in providing protection
in NHP models," said Dr. Smith. "Our vaccine is the first subunit
Ebola GP-based vaccine to provide protection in non-human primates
and this confirmatory data strongly supports the advancement of
this program. Importantly, although we developed our Ebola GP
Vaccine from the Makona strain, which is the strain responsible for
the recent Ebola epidemic in West Africa, these primates were
challenged with the Kikwit strain of Ebola, which suggests that our
vaccine candidate may be protective across different variants of
the virus."
Novavax is currently conducting a Phase 1 clinical trial of its
Ebola GP Vaccine in healthy subjects. It expects top-line data from
this trial in mid-2015.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine
company committed to delivering novel products to prevent a broad
range of infectious diseases. Our recombinant nanoparticles and
Matrix-M™ adjuvant technology are the foundation for groundbreaking
innovation that improves global health through safe and effective
vaccines. Additional information about Novavax is available on
the company's website, www.novavax.com.
Forward-Looking Statements
Statements contained in this release, including those relating
to the closing of the offering, and those statements using words
such as "expects" and "intends" are forward-looking statements that
involve a number of risks and uncertainties that could cause actual
results to differ materially from those in the forward-looking
statements. These risks and uncertainties include, but are not
limited to: the possible adverse impact on the market price of our
shares of common stock due to the dilutive effect of the securities
to be sold in the offering; our planned use of the proceeds from
this offering; capital market risks; our ability to raise
additional capital when needed; and other risk factors identified
from time to time in the reports we file with Securities and
Exchange Commission (SEC), including our Annual Report on Form
10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form
8-K, which are available at www.sec.gov. We caution investors not
to place considerable reliance on the forward-looking statements
contained in this press release. You are encouraged to read our
filings with the SEC, available at sec.gov, for a discussion
of these and other risks and uncertainties. The forward-looking
statements in this press release speak only as of the date of this
document, and we undertake no obligation to update or revise any of
the statements. Our business is subject to substantial risks and
uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
CONTACT: Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations
ir@novavax.com
240-268-2000
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024